Fewer than 1 in 3 children with hepatitis C (HCV) see a clinician for care, and fewer than 1 in 8 receive treatment.

These scientists sought to answer a simple question. They ended up stumbling upon a discovery that could pave the way for a ...

Pfizer’s sasanlimab, when used with standard of care, reduced the likelihood of disease recurrence or progression, death due ...

Pfizer has linked its PD-1 inhibitor to a 32% reduction in the risk of disease-related events in a phase 3 bladder cancer ...

Penyakit Roseola Infantum biasa mengincar bayi dan balita. Pelajari penyebab dan gejalanya sebelum terlambat demi kesehatan ...

Six abstracts accepted for presentation includes post hoc analyses and real-world evidence for ZYMFENTRA® (infliximab-dyyb) Findings reinforce clinical decision-making in long-term management of ...